Abstract
Cerebral vasogenic edema and microhemorrhages are potential safety concerns for compounds intended to treat subjects with Alzheimer’s disease (AD) by targeting amyloid β (Aβ). Ponezumab (PF-04360365) is an investigational anti-Aβ monoclonal antibody. Two hundred female mice (APPK670N;M671L; Tg2576) 16–19 months old received an aglycosylated CHO-derived murine surrogate of ponezumab by intraperitoneal administration once weekly for up to 26 weeks at doses of 0, 10, 30, or 100 mg/kg. Drug exposure and plasma Aβ levels increased with increasing dose. After 26 weeks, the 100 mg/kg group had significantly greater plasma levels of Aβ1-x and Aβx-40 than the vehicle group (p < 0.001). Brain microhemorrhages were identified histologically using hematoxylin and eosin and/or Perls’ Prussian blue iron staining. The incidence in the vehicle group was equal to or higher than those of the treated groups. There was no evidence of vasogenic edema. In summary, intraperitoneal administration of a murine surrogate of ponezumab to aged Tg2576 mice for up to 6 months did not produce any compound-related brain microhemorrhage or other pathologies.
Keywords: Microhemorrhage, murine surrogate, ponezumab (PF-04360365), safety, Tg2576 mice, Aβ, CAA, Cerebral vasogenic edema, amyloid plaques, brain magnetic resonance imaging, cell-mediated cytotoxicity.
Current Alzheimer Research
Title:Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice
Volume: 9 Issue: 9
Author(s): Gary B. Freeman, Thomas P. Brown, Karin Wallace and Kelly R. Bales
Affiliation:
Keywords: Microhemorrhage, murine surrogate, ponezumab (PF-04360365), safety, Tg2576 mice, Aβ, CAA, Cerebral vasogenic edema, amyloid plaques, brain magnetic resonance imaging, cell-mediated cytotoxicity.
Abstract: Cerebral vasogenic edema and microhemorrhages are potential safety concerns for compounds intended to treat subjects with Alzheimer’s disease (AD) by targeting amyloid β (Aβ). Ponezumab (PF-04360365) is an investigational anti-Aβ monoclonal antibody. Two hundred female mice (APPK670N;M671L; Tg2576) 16–19 months old received an aglycosylated CHO-derived murine surrogate of ponezumab by intraperitoneal administration once weekly for up to 26 weeks at doses of 0, 10, 30, or 100 mg/kg. Drug exposure and plasma Aβ levels increased with increasing dose. After 26 weeks, the 100 mg/kg group had significantly greater plasma levels of Aβ1-x and Aβx-40 than the vehicle group (p < 0.001). Brain microhemorrhages were identified histologically using hematoxylin and eosin and/or Perls’ Prussian blue iron staining. The incidence in the vehicle group was equal to or higher than those of the treated groups. There was no evidence of vasogenic edema. In summary, intraperitoneal administration of a murine surrogate of ponezumab to aged Tg2576 mice for up to 6 months did not produce any compound-related brain microhemorrhage or other pathologies.
Export Options
About this article
Cite this article as:
B. Freeman Gary, P. Brown Thomas, Wallace Karin and R. Bales Kelly, Chronic Administration of an Aglycosylated Murine Antibody of Ponezumab Does Not Worsen Microhemorrhages in Aged Tg2576 Mice, Current Alzheimer Research 2012; 9 (9) . https://dx.doi.org/10.2174/156720512803569064
DOI https://dx.doi.org/10.2174/156720512803569064 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
Call for Papers in Thematic Issues
New Advances in the Prevention, Diagnosis, Treatment, and Rehabilitation of Alzheimer's Disease
Aims and Scope: Introduction: Alzheimer's disease (AD) poses a significant global health challenge, with an increasing prevalence that demands concerted efforts to advance our understanding and strategies for prevention, diagnosis, treatment, and rehabilitation. This thematic issue aims to bring together cutting-edge research and innovative approaches from multidisciplinary perspectives to address ...read more
Current updates on the Role of Neuroinflammation in Neurodegenerative Disorders
Neuroinflammation is an invariable hallmark of chronic and acute neurodegenerative disorders and has long been considered a potential drug target for Alzheimer?s disease (AD) and dementia. Significant evidence of inflammatory processes as a feature of AD is provided by the presence of inflammatory markers in plasma, CSF and postmortem brain ...read more
Deep Learning for Advancing Alzheimer's Disease Research
Alzheimer's disease (AD) poses a significant global health challenge, with an increasing number of individuals affected yearly. Deep learning, a subfield of artificial intelligence, has shown immense potential in various domains, including healthcare. This thematic issue of Current Alzheimer Research explores the application of deep learning techniques in advancing our ...read more
Diagnostic and therapeutic biomarkers of dementia
Dementia affects 18 million people worldwide. Dementia is a syndrome of symptoms caused by brain disease, usually chronic or progressive, clinically characterized by multiple impairments of higher cortical functions such as memory, thinking, orientation, and learning. In addition, in the course of dementia, cognitive deficits are observed, which often hinder ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Risk Factors for Cardiovascular Disease in Psoriasis: Relation to Inflammation Assessed by the Severity and Duration of Illness
Inflammation & Allergy - Drug Targets (Discontinued) Non-Classical Therapeutic Approach in the Treatment of Alzheimer's Disease: A Mini Review
Letters in Drug Design & Discovery Vascular Lesion Thickness in the Lenticulostriate Artery Region Serves as a Biomarker for Early Neurological Deterioration
Current Neurovascular Research Meet Our Editorial Board Member
Current Alzheimer Research The Paths to Neurodegeneration in Genetic Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Neuroinflammation in Alzheimer’s Disease: Microglia, Molecular Participants and Therapeutic Choices
Current Alzheimer Research Nanoparticlized System: Promising Approach for the Management of Alzheimer’s Disease through Intranasal Delivery
Current Pharmaceutical Design Role of Autophagy in Alzheimer’s Disease
Current Enzyme Inhibition DNA Repair in Premature Aging Disorders and Neurodegeneration
Current Aging Science Cognitive Stimulation: The Evidence Base for its Application in Neurodegenerative Disease
Current Alzheimer Research Targeting Striatal Metabotropic Glutamate Receptor Type 5 in Parkinson’s Disease: Bridging Molecular Studies and Clinical Trials
CNS & Neurological Disorders - Drug Targets Frontotemporal Dementia Caused by CHMP2B Mutations
Current Alzheimer Research Clinical, Immunological and Therapeutic Aspects of Autoimmune Encephalitis
Recent Patents on CNS Drug Discovery (Discontinued) Small Ruminant Lentiviruses and Human Immunodeficiency Virus: Cousins that Take a Long View
Current HIV Research Polyphenols in Disease: from Diet to Supplements
Current Pharmaceutical Biotechnology NMDA Receptors and Learning and Memory Processes
Current Drug Targets The Regulation of Brain Nucleoside Utilization
Current Metabolomics Butyrylcholinesterase K and Apolipoprotein ε4 Affect Cortical Thickness and Neuropsychiatric Symptoms in Alzheimer’s Disease
Current Alzheimer Research <i>In-silico</i> Prediction of the Beta-carboline Alkaloids Harmine and Harmaline as Potent Drug Candidates for the Treatment of Parkinson’s disease
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Autoimmunity and Frontotemporal Dementia
Current Alzheimer Research